TAP1 and cancer: Thus, it is reasonable to speculate that there may be genomic alterations that counteract the increased levels of TAP1. Genetic alteration analysis revealed a maximum frequency of TAP1 gene alterations of 8% in the tested pan-cancer cohort, and mutation types were non-specific, indicating that they were unlikely to contribute substantially to cancer development.